Alzheimer’s Disease
  • Swanson C, et al. Increasing Representation and Diversity in Clinical Trials of Alzheimer’s Disease: Recruitment of Ethnically Diverse Participants With Alzheimer’s Disease in the Phase 1 ASCENT Clinical Trials of PRX012. Poster presented at CTAD 2024; October 29-November 1, 2024; Madrid, Spain and Virtual.
  • Silber A, et al. Patient Considerations in the Development and Delivery of Novel Treatments for Alzheimer’s Disease. Poster presented at CTAD 2024; October 29-November 1, 2024; Madrid, Spain and Virtual.
  • Swanson C, et al. Phase 1 Single and Multiple Dose Clinical Trials (ASCENT-1 and ASCENT-2) for Dose-Finding of PRX012 in Participants With Biologically Confirmed Alzheimer’s Disease. Poster presented at AAIC 2024; July 28-August 1, 2024; Philadelphia, PA and Virtual. View abstract
  • Schindler SE, et al. Acceptable Performance of Blood Biomarker Tests of Amyloid Pathology — Recommendations From the Global CEO Initiative on Alzheimer’s Disease. Nat Rev Neurol. 2024; https://doi.org/10.1038/s41582-024-00977-5. PubMed
  • Silber A, et al. US Infusion Center Capacity to Accommodate Anti-Amyloid Treatments for Alzheimer’s Disease: A Quantitative Survey. Poster presented at ISPOR US 2024; May 5-8, 2024; Atlanta, GA and Virtual. View presentation
  • Head S, et al. Systematic in Silico Analysis of Clinically Tested Drugs for Reducing Amyloid Beta Plaque Accumulation in Alzheimer’s Disease. Poster presented at CTAD 2023; October 24-27, 2023; Boston, MA and Virtual. View presentation
  • Tourino C, et al. Immunological Response to Dual Aβ/Tau Vaccine PRX123 Surrogate and Effects on Brain Amyloid Plaques in Rapidly Depositing Transgenic Animal Model. Poster presented at AAIC 2023; July 16-20, 2023; Amsterdam, Netherlands. View presentation
  • Martényi F, et al. PRX005, A Novel Anti-MTBR Tau Humanized Monoclonal Antibody: Results From a First-in-Human Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Clinical Trial. Poster presented at AAIC 2023; July 16-20, 2023; Amsterdam, Netherlands. Poster 74181. Partnership with BMS. View presentation
  • Campbell B, et al. Binding Characteristics of Surrogate PRX012 Demonstrate Potent Engagement of Toxic Aβ Protofibrils and Robust Clearance of Pyroglutamate-Modified Aβ. Presented at AD/PD 2023; March 28-April 1, 2023; Gothenburg, Sweden. View presentation
  • Barbour R, et al. Development of Dual Aβ-Tau Vaccines for the Treatment and Prevention of Alzheimer’s Disease. Oral presentation at AD/PD 2022; March 15-20, 2022, Barcelona, Spain. View presentation
  • Barbour R, et al. Development of a Dual Aβ/Tau Vaccine for the Prevention of Alzheimer Disease. Poster presented at AAIC; July 26-30, 2021; Denver, CO and Virtual. View presentation
  • Dolan P,  et al. Microtubule Binding Region (MTBR)-Specific Antibody PRX005 Prevents Pathological Tau Progression via Blockade of Neuronal Internalization. Oral presentation at AD/PD 2021; March 9-14, 2021; Virtual. Partnership with BMS. View presentation
  • Tam S, et al. PRX012 Induces Microglia-Mediated Clearance of Pyroglutamate-Modified and Unmodified Aß in Alzheimer’s Disease Brain Tissue. Poster presented at AAIC; July 26-30, 2021; Denver, CO and Virtual. View presentation
  • Skov M, et al. Novel Amyloid β Monoclonal Antibodies with Superior Binding Properties: Potential for More Convenient Dosing and Greater Patient Access in Alzheimer’s Disease. Poster presented at CTAD 2020; November 4-7, 2020; Boston, MA and Virtual. View presentation
  • Barbour R, et al. Development of a Dual Aβ/Tau Vaccine for the Prevention and Treatment of Alzheimer’s Disease. Poster presented at CTAD 2020; November 4-7, 2020; Boston, MA and Virtual. View presentation
  • Zago W, et al. Vascular Alterations in PDAPP Mice After Anti-Aβ Immunotherapy: Implications for Amyloid-Related Imaging Abnormalities. Alzheimers Dement. 2013;9:S105-S115. PubMed
  • Zago W, et al. Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific. J Neurosci. 2012;32:2696-2702. PubMed
  • Bard F, et al. Sustained Levels of Antibodies Against Aβ in Amyloid-Rich Regions of the CNS Following Intravenous Dosing in Human APP Transgenic Mice. Exp Neurol. 2012;238:38-43. PubMed
  • Basi GS, et al. Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid β-Related Behavioral Deficits in a Mouse Model of Alzheimer Disease. J Biol Chem. 2010;285:3417-3427. PubMed
  • Lee M, et al. Aβ42 Immunization in Alzheimer's Disease Generates Aβ N-Terminal Antibodies. Ann Neurol. 2005;58:430-435. PubMed
  • Bard F, et al. Peripherally Administered Antibodies Against Amyloid β-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease. Nat Med. 2000;6:916-919. PubMed
  • Schenk D, et al. Immunization With Amyloid-β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse. Nature. 1999;400:173-177. PubMed
  • Games D, et al. Alzheimer-Type Neuropathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein. Nature. 1995;373:523-527. PubMed
  • Haass C, et al. Amyloid β-Peptide Is Produced by Cultured Cells During Normal Metabolism. Nature. 1992;359:322-325. PubMed
Parkinson’s Disease
  • Pagano G, et al. Prasinezumab Slows Motor Progression in Rapidly Progressing Early-Stage Parkinson’s Disease. Nat Med. 2024;30:1096-1103. Partnership with Roche. PubMed
  • Pagano G, et al. PASADENA Long-Term Open-Label Extension Continue to Show Reduced Motor and Functional Progression in Prasinezumab-Treated Individuals With Early-Stage Parkinson’s Disease Compared to a Real-World Data Arm. Presented at AD/PD 2024; March 5-9, 2024; Lisbon, Portugal. Partnership with Roche. View abstract
  • Nikolcheva T, et al. A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data. Oral presented at AD/PD 2024; March 5-9, 2024; Lisbon, Portugal. Partnership with Roche. View abstract
  • Kwasny D, et al. Slower Progression of Digital Acoustic Speech Measures in Early Parkinson’s Disease Under Prasinezumab During the First 52 Weeks of the PASADENA Study. Virtual oral presented at AD/PD 2024; March 5-9, 2024; Lisbon, Portugal. Partnership with Roche. View abstract
  • Barbour R, et al. Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies. Poster presented at AD/PD 2022; March 15-20, 2022, Barcelona, Spain. Poster 52980. View presentation
  • Pagano G, et al. Trial of Prasinezumab in Early-Stage Parkinson's Disease. N Engl J Med. 2022;387:421-432. Partnership with Roche. PubMed
  • Pagano G, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021;12:705407. Partnership with Roche. PubMed
  • Jankovic J, et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients with Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018;75:1206-1214. Partnership with Roche. PubMed
  • Schenk DB, et al. First-in-Human Assessment of PRX002, an Anti-α-Synuclein Monoclonal Antibody, in Healthy Volunteers. Mov Disord. 2017;32:211-218. Partnership with Roche. PubMed
  • Games D, et al. Reducing C-Terminal-Truncated α-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models. J Neurosci. 2014;34:9441-9454. PubMed
  • Games D, et al. Axonopathy in an α-Synuclein Transgenic Model of Lewy Body Disease Is Associated with Extensive Accumulation of C-Terminal-Truncated α-Synuclein. Am J Pathol. 2013;182:940-953. PubMed